Leukemia, a devastating hematological malignancy, has long been a formidable challenge in the realm of oncology. At Alfa Cytology, we have dedicated to unraveling the complexities of this disease, driven by a relentless pursuit of innovative solutions.
Introduction to Leukemia
Leukemia is a type of cancer that originates in the haematopoietic tissues (mainly the bone marrow and lymphatic system).
Fig.1 Cytology of leukemia.
Leukemia is broadly classified into four main types:
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML)
Pathogenesis of Leukemia
One of the hallmarks of leukemia is the accumulation of genetic mutations, which can disrupt the normal regulation of cell growth, proliferation, and survival.
Fig.2 NF-κB pathway mutations in chronic lymphocytic leukaemia. (Fabbri, G., & Dalla-Favera, R., 2016)
Therapy Development for Leukemia
Promising leukemia pipeline therapies in various stages of development include:
| Drugs |
Company |
Phase |
MoA |
RoA |
| Omidubicel |
Gamida Cell |
Registered |
Cell replacements |
Intravenous |
| Uproleselan |
GlycoMimetics |
Phase III |
E-selectin inhibitors |
Intravenous |
| Pevonedistat |
Takeda Oncology |
Phase III |
NEDD 8 activating enzyme inhibitors |
Intravenous |
| SKLB1028 |
CSPC Ouyi Pharmaceutical |
Phase III |
Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors |
Oral |
| BPX-501 |
Bellicum Pharmaceuticals |
Phase II |
Immunologic cytotoxicity; T lymphocyte replacements |
Intravenous |
| ALT 803 |
ImmunityBio |
Phase II |
Interleukin-15 receptor agonists |
Intravenous |
Our Services
At Alfa Cytology, with a team of highly skilled and experienced biological experts who have worked in the industry for many years, our company understands the unique challenges associated with leukemia therapy and is committed to providing cutting-edge solutions. We have developed a profound understanding of the molecular mechanisms of leukemia and have conducted extensive research in this field.
Preclinical animal models play a crucial role in the development of novel leukemia therapies. We offer a specialized service for the development and characterization of advanced leukemia animal models.
Animal Models
- Spontaneous ALL Animal Models
- Chemical-Induced ALL Animal Models
- Xenotransplantation ALL Animal Models
- Transgenic ALL Animal Models
Cell Line Models
- K-562
- KU-812
- Bv-173
- EM-2/EM-3
- NALM-1
- JK-1
In Vitro 3D AML Models
- Synthetic Scaffold-Based 3D Models
- Biologic Scaffold-Based 3D Models
- Dynamic 3D In Vitro Models
Optional Species
- Mouse
- Rats
- Zebrafish
- Non-human Primates
- Others
For more information about our leukemia research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us at Alfa Cytology. Our dedicated team of experts is committed to collaborating with healthcare providers and research institutions to drive progress in the fight against leukemia.
Reference
- Fabbri, G., & Dalla-Favera, R. (2016). The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer, 16(3), 145-162.
For research use only.
Related Services
